Table 2.
Characteristics of enrolled patients reported in SUSTAIN FORTE, SUSTAIN 7, and AWARD-11
| Trial name | SUSTAIN FORTE | SUSTAIN 7a | AWARD-11 |
|---|---|---|---|
| Treatment (pooled treatment arms) | Semaglutide 2.0 mg and semaglutide 1.0 mg | Semaglutide 1.0 mg and dulaglutide 1.5 mg | Dulaglutide 1.5 mg, dulaglutide 3.0 mg, and dulaglutide 4.5 mg |
| N | 961 | 599 | 1842 |
| Mean age (SD), y | 58.0 (10.0) | 55.6 (10.6) | 57.1 (10.0) |
| Female, % | 41.4 | 44.4 | 48.8 |
| Race, n (%) | |||
| White | 847 (88) | 463 (77) | 1580 (86) |
| Asian | 69 (7) | 93 (16) | 45 (2.4) |
| Black or African American | 43 (4) | 36 (6) | 82 (4.5) |
| American Indian or Alaska Native | 1 (<1) | 0 | 88 (4.8) |
| Native Hawaiian or Pacific Islander | 0 | 0 | 5 (<1) |
| Other | 1 (<1) | 7 (1) | 0 |
| Multiple | 0 | 0 | 42 (2.3) |
| Mean HbA1c (SD), % | 8.9 (0.6) | 8.2 (0.9) | 8.6 (1.0) |
| Mean body weight (SD), kg | 99.3 (23.5) | 94.5 (21.4) | 95.7 (20.3) |
| Mean BMI (SD), kg/m2 | 34.6 (7.0) | 33.3 (6.5) | 34.2 (6.3) |
| Mean T2D duration (SD), y | 9.5 (6.2) | 7.5 (5.7) | 7.6 (5.7) |
| Mean fasting glucoseb (SD), mg/dL | 194.4 (50.0) | 174.8 (44.0) | 184.1 (51.5) |
| Mean DBP (SD), mmHg | 80.9 (9.4) | 80.8 (8.9) | 78.7 (9.0) |
| Mean SBP (SD), mmHg | 134.4 (14.0) | 132.6 (14.1) | 131.8 (14.1) |
| Mean pulse rate (SD), beats/minute | 75.9 (10.1) | 75.1 (10.5) | 75.5 (10.0) |
| Mean eGFR (SD), mL/min/1.73 m2 | 93.4 (16.9) | 97.2 (16.0) | 93.5 (18.1) |
| Mean lipid levels (SD), mg/dL | |||
| Total cholesterol | Not collected | 183.2 (44.7) | 177.5 (NR)c |
| HDL cholesterol | Not collected | 45.0 (10.8) | 45.6 (NR)c |
| LDL cholesterol | Not collected | 103.8 (38.8) | 93.4 (NR)c |
| VLDL cholesterol | Not collected | Not collected | 34.5 (NR)c |
| Triglycerides | Not collected | 183.3 (112.6) | 202.4 (NR)c |
Abbreviations: AWARD, A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes; BMI, body mass index; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NR, not reported; SUSTAIN, A Research Study to Compare Two Doses of Semaglutide Taken Once Weekly in People With Type 2 Diabetes; T2D, type 2 diabetes; VLDL, very low-density lipoprotein.
a Note SUSTAIN 7 also included semaglutide 0.5 mg and dulaglutide 0.75 mg; however, these were not treatments of interest for the current analysis.
b Fasting plasma glucose in SUSTAIN FORTE and SUSTAIN 7; fasting serum glucose in AWARD-11.
c Pooled data are not presented in the AWARD-11 publication. Mean values have been calculated as weighted average.